Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to $1.2 million.

  • Taysha Gene Therapies' Depreciation & Amortization (CF) fell 33.33% to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 16.36%. This contributed to the annual value of $1.2 million for FY2024, which is 11.07% down from last year.
  • As of FY2024, Taysha Gene Therapies' Depreciation & Amortization (CF) stood at $1.2 million, which was down 11.07% from $1.4 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Depreciation & Amortization (CF) peaked at $1.4 million during FY2023, and registered a low of $9,000 during FY2020.
  • In the last 3 years, Taysha Gene Therapies' Depreciation & Amortization (CF) had a median value of $1.2 million in 2024 and averaged $1.3 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Depreciation & Amortization (CF) surged by 5,455.56% in 2021, and later declined by 11.07% in 2024.
  • Yearly analysis of 5 years shows Taysha Gene Therapies' Depreciation & Amortization (CF) stood at $9,000 in 2020, then spiked by 5,455.56% to $500,000 in 2021, then soared by 140.00% to $1.2 million in 2022, then increased by 16.67% to $1.4 million in 2023, then declined by 11.07% to $1.2 million in 2024.